Germany’s Merck KGaA has presented detailed results from cohort B of the global Phase II WILLOW study of enpatoran, an ...

German science and technology firm Merck KGaA (MRK: DE) has moved a step closer to introducing a new therapy for tenosynovial ...

Plant Services Smart Minute is a content based enewsletter where readers will find exclusive content, relevant industry news, useful case studies, access to Plant Services on-demand webcasts, and ...

It remains unclear when production will start. More retail could fill site along K-10 near Panasonic Merck plans $895M ...

Triple-negative breast cancer (TNBC) - closeup view 3d illustration] Nemes Laszlo/iStock via Gilead Sciences (NASDAQ:GILD [ announced Saturday that its antibody-drug conjugate Trodelvy, in ...

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in De Soto, Kansas. Trump to sign order on drug prices as early as next week, Politico reports ...

(MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus chemotherapy for the ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

MRK), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health’s manufacturing facility in De Soto, Kansas.

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants. The U.S. Food ...